The market has been high on Arcus Biosciences Inc (RCUS) stock recently. RCUS gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.
Arcus Biosciences Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on RCUS!
What is Stock Sentiment?
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With RCUS Stock Today?
Arcus Biosciences Inc (RCUS) stock is lower by -3.91% while the S&P 500 is higher by 0.56% as of 10:30 AM on Wednesday, Jul 21. RCUS is lower by -$1.25 from the previous closing price of $32.00 on volume of 270,910 shares. Over the past year the S&P 500 has gained 33.68% while RCUS is higher by 24.49%. RCUS lost -$2.80 per share in the over the last 12 months.
To see InvestorsObserver's Sentiment Score for Arcus Biosciences Inc click here.
More About Arcus Biosciences Inc
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies.
Click Here to get the full Stock Report for Arcus Biosciences Inc stock.